Sedana Medical AB (publ), Interim report Q2, 2018
The registration process for the United States commenced and European study resumed at full speedFinancial Summary April-June · Net sales during the third quarter amounted to 14 485 (9 549) KSEK corresponding to an increase of 52% compared with the same period in 2017. · Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to -1 006 (673) KSEK. This corresponds to an EBITDA margin of -6,9% (7,1%). · Earnings before interest and taxes (EBIT) amounted to -2 007 (408) KSEK, which corresponds to an EBIT margin of -13,9% (4,3%). · Cash flow from